BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Gemini Axes 80% of Workforce, Names Interim CEO, in Restructuring

  Gemini will undertake a corporate restructuring that will see a drastic 80% of its workforce laid off.

  March 1, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  New Launches Focus On Non-Coding RNAs and Chronic Kidney Disease

  Two new biotech companies launched today: NextRNA to focus on non-coding RNA technology, and Pathalys, with a clinic-ready licensed compound and plans to enter Phase III trials.

  March 1, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Complex CRISPR Patent Decision Benefits Broad Institute, Editas

  The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to Broad, not UC Berkeley.

  March 1, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Sanofi and Regeneron’s Dupixent Poised to Keep Shining in 2022

  In 2021, Sanofi earned about $4.2 billion from Dupixent sales, and Regeneron earned about $1.8 billion.

  March 1, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Study: Pfizer-BioNTech Vaccine Much Weaker in Kids Against Omicron and More

  The study, which has yet to be peer-reviewed, found the Pfizer-BioNTech vaccine was only about 12% effective for children ages 5 to 11 years against the Omicron variant.

  March 1, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Rejects Gilead’s Long-Acting HIV Drug Over Vial Issues

  The FDA rejected Gilead’s New Drug Application, citing Chemistry Manufacturing and Controls (CMC) problems associated with the compatibility of the drug with the proposed container vial.

  March 1, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Intellia’s CRISPR Therapy Shows it can Stand the Test of Time

  Positive interim data from the global Phase I trial of single-dose NTLA-2001 demonstrated a mean serum TTR reduction of 93% at the highest dose level of 1.0 mg/kg by day 28.

  March 1, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Neurimmune ATTR-CM Asset Nets Potential $700M Plus From AstraZeneca

  AstraZeneca and Neurimmune have signed an exclusive global collaboration and licensing deal to develop, manufacture and commercialize NI006 for ATTR-CM.

  March 1, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  J&J, Legend Introduce New CAR-T Therapy, Carvykti to Multiple Myeloma Market

  Johnson & Johnson’s partner, Legend Biotech, has been awarded FDA approval for its (CAR-T) therapy, Carvykti, for the treatment of multiple myeloma disease.

  March 1, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Pfizer Fails in C.diff, BMS Announces Priority Review for Opdivo in NSCLC

  Pfizer’s Clostridioides difficile infection vaccine failed to hit the mark, BMS announced priority review for Opdivo in resectable Non-Small Cell Lung Cancer, and Saol enlists help from GeneDx.

  March 1, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh